Ralph Preiss
Actelion
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ralph Preiss as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:05 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03187678 · Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial HypertensionActelion · completed · Pulmonary Arterial Hypertension · study director
- Ph2NCT02260557 · Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisActelion · completed · Raynaud's Phenomenon Secondary to Systemic Sclerosis · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:05 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Selexipag for the Treatment of Pulmonary Arterial Hypertension.N Engl J Med · 2015821 citationsRCR 31.7
- 166 citationsRCR 4.5
- Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.BMC Musculoskelet Disord · 2011121 citationsRCR 3.1
- Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.J Clin Pharmacol · 2003113 citationsRCR 3.0
- Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.Eur Respir J · 2017103 citationsRCR 4.7
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.J Am Coll Cardiol · 201897 citationsRCR 4.3
- 90 citationsRCR 2.7
- Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers.Int J Clin Pharmacol Ther · 199888 citationsRCR 2.7
- Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.Circulation · 201979 citationsRCR 4.0
- Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.Am J Cardiovasc Drugs · 201872 citationsRCR 3.4